Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of AK104 plus AK117 with or without chemotherapy in advanced malignant tumors
CTR20220284Phase 2Active
- Sponsor
- Akeso, Inc.
- Start
- Aug 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab, ligufalimab in advanced nonhematological malignancy, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Akeso, Inc.. Started Aug 2022; status: active.
02
Drugs
cadonilimabligufalimab
03
Conditions
advanced nonhematological malignancygastric adenocarcinomagastroesophageal junction adenocarcinomaEsophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20220284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220284.